BIO vs OCUL · rev $2.58B vs rev $24.3M
BIO (BIO) versus Ocular Therapeutix Inc (OCUL) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 287.0% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported OCUL revenue for 2026-06-30 was $24.3M. Net income was -$167.4M. OCUL currently screens at market cap $1.76B.
BIO currently screens at market cap $0. OCUL currently screens at market cap $1.76B.
Not investment advice. Open the BIO and OCUL stock pages for the full models.
Not investment advice.